+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Viral Clearance - Global Strategic Business Report

  • PDF Icon

    Report

  • 194 Pages
  • May 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4806194
The global market for Viral Clearance is estimated at US$566.2 Million in 2023 and is projected to reach US$1.8 Billion by 2030, growing at a CAGR of 18.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Recombinant Proteins Application segment, which is expected to reach US$430.4 Million by 2030 with a CAGR of a 18.6%. The Blood and Blood Products Application segment is also set to grow at 16% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $178.6 Million in 2023, and China, forecasted to grow at an impressive 17.9% CAGR to reach $319.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Viral Clearance Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Viral Clearance Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Viral Clearance Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Avance Biosciences Inc., BSL BIOSERVICE Scientific Laboratories Munich GmbH, Charles River Laboratories International, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 41 Featured):

  • Avance Biosciences Inc.
  • BSL BIOSERVICE Scientific Laboratories Munich GmbH
  • Charles River Laboratories International, Inc.
  • Clean Cells Inc.
  • Lonza Group AG
  • Merck KgaA
  • SGS SA
  • Sigma-Aldrich Corporation
  • Texcell, Inc.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Viral Clearance - Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Viral Clearance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World 7-Year Perspective for Viral Clearance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 4: World 7-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Blood and Blood Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 6: World 7-Year Perspective for Blood and Blood Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 8: World 7-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 10: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 12: World 7-Year Perspective for Pharmaceutical & Biotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 14: World 7-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 15: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 16: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 18: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 19: World Viral Clearance Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 21: USA 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 22: USA Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 23: USA 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
CANADA
  • Table 24: Canada Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 25: Canada 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 26: Canada Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
JAPAN
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 28: Japan Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 29: Japan 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 30: Japan Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 31: Japan 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
CHINA
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 32: China Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: China 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 34: China Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 35: China 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
EUROPE
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 36: Europe Recent Past, Current & Future Analysis for Viral Clearance by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 37: Europe 7-Year Perspective for Viral Clearance by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • Table 38: Europe Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: Europe 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 40: Europe Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 41: Europe 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
FRANCE
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 42: France Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 43: France 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 44: France Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: France 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
GERMANY
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 46: Germany Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 47: Germany 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 48: Germany Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 49: Germany 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
ITALY
  • Table 50: Italy Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Italy 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 52: Italy Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 53: Italy 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
UNITED KINGDOM
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 54: UK Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 55: UK 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 56: UK Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: UK 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
REST OF EUROPE
  • Table 58: Rest of Europe Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 59: Rest of Europe 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 60: Rest of Europe Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 61: Rest of Europe 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
ASIA-PACIFIC
  • Viral Clearance Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Asia-Pacific 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 64: Asia-Pacific Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 65: Asia-Pacific 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
REST OF WORLD
  • Table 66: Rest of World Recent Past, Current & Future Analysis for Viral Clearance by Application - Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 67: Rest of World 7-Year Perspective for Viral Clearance by Application - Percentage Breakdown of Value Sales for Recombinant Proteins, Blood and Blood Products, Vaccines and Other Applications for the Years 2024 & 2030
  • Table 68: Rest of World Recent Past, Current & Future Analysis for Viral Clearance by End-Use - Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: Rest of World 7-Year Perspective for Viral Clearance by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology, CROs, Academic Research Institutes and Other End-Uses for the Years 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Avance Biosciences Inc.
  • BSL BIOSERVICE Scientific Laboratories Munich GmbH
  • Charles River Laboratories International, Inc.
  • Clean Cells Inc.
  • Lonza Group AG
  • Merck KgaA
  • SGS SA
  • Sigma-Aldrich Corporation
  • Texcell, Inc.

Table Information